Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea

Koo, Chung Mo; Kim, Se Hee; Lee, Joon Soo; Park, Byung Joo; Lee, Hae Kook; Kim, Heung Dong; Kang, Hoon Chul

doi:10.3346/jkms.2020.35.e427

Cited by 20 publications

(15 citation statements)

References 24 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective study conducted in Korea in children with Lennox-Gastaut syndrome and Dravet syndrome found seizure reduction in approximately 50% of patients and adverse events in 36%. 8 Of note, this is similar to the results of the present study. There are few previous reports of studies on refractory epilepsy and CBD in Asians, and the possibility of differences in efficacy rates by race is a subject for future research.…”

Section: Discussionsupporting

confidence: 92%

“…Due to the strict cannabis regulations in Asia and the limited number of countries where medical marijuana can be used legally, reports on epilepsy in Mongoloid populations are limited, with only 34 cases of Dravet syndrome and Lennox-Gastaut syndrome reported by a Korean research team in 2020. 8 Japan's regulatory law on cannabis, the Cannabis Control Law, was enacted in 1948 and has not been radically revised since its enactment. Buds and leaves are not permitted in the regulations but stems and seeds are permitted.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cannabidiol (CBD) Reduces Epileptic Seizures in the Asian Population: Cross-sectional Study for Intractable Epilepsy Patients in Japan

Masataka¹,

Sugiyama²,

Takumi³

et al. 2022

NeuroAsia

View full text Add to dashboard Cite

Purpose of study: Despite very strict cannabis regulations in Japan, some cannabidiol (CBD) products have been legally distributed since 2013 and taken by some epilepsy patients. However, its efficacy and safety have not been evaluated. Basic procedures: A self-administered questionnaire was sent to 38 patients with intractable epilepsy who were taking CBD. The questionnaire sought information on patient background (sex, age) and medical history (diagnosis, type of seizures), characteristics of CBD use (frequency, route of administration), and the safety of CBD use (adverse events, side effects). Patients were also asked about changes in seizure frequency, intensity, and duration; effect on sleep; effect on daytime activity/vitality; increase/decrease in antiepileptic drugs dosage; quality of life (QOL); and caregiver-assessed QOL. Findings: Responses were received from 28 of 38 patients. The median CBD intake was 12.0 mg/kg/day. Nine patients (32.1%) were suspected of having an adverse event, but all were mild and no patients discontinued CBD due to adverse events. Fifteen patients (53.6%) reported a decrease in seizure frequency, and 2 patients (7.1%) showed complete resolution of seizures. No significant correlation was found between the patient’s diagnosis and the seizure type or efficacy. Conclusions: This is the first cross-sectional study of CBD users in Japan, suggesting that CBD may be an effective option for Asian patients with refractory epilepsy, regardless of diagnosis or seizure type.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Cannabidiol (CBD) Reduces Epileptic Seizures in the Asian Population: Cross-sectional Study for Intractable Epilepsy Patients in Japan

Masataka¹,

Sugiyama²,

Takumi³

et al. 2022

NeuroAsia

View full text Add to dashboard Cite

show abstract

“…In another study on effective dose ranges for convulsive seizures in DS, adjunctive CBD led to reductions in convulsive seizure frequency, with a better safety and tolerability profile for the 10 mg/kg/day dose [13]. Another study group in South Korea reported CBD's effects on patients with LGS and DS, stating that substantial proportions of patients experienced a ≥50% seizure frequency reduction at 3-month (LGS 32.3% and DS 30%) and 6-month (LGS 29.4% and DS 20%) follow-ups, at a mean dosage of 10 mg/kg/ day [14]. In our study, 16 (53.3%) patients achieved ≥50% seizure reduction, with a median dosage of 10.7 mg/kg/day (IQR, 7.2 to 12.5).…”

Section: Discussionmentioning

confidence: 99%

Cannabidiol Treatment for Lennox-Gastaut Syndrome at a Single Tertiary Center in South Korea

et al. 2023

View full text Add to dashboard Cite

This study evaluated the efficacy and tolerability of cannabidiol (CBD) as an add-on therapy for childhood-onset Lennox-Gastaut syndrome (LGS). Methods: This retrospective study enrolled patients who visited the Department of Pediatric Neurology at Asan Medical Center from March 2019 to February 2022 and were treated with CBD. Electronic medical records and clinically relevant factors (including the type of epilepsy and seizures, etiology, and the number of concomitantly used anti-epileptic drugs) were reviewed. The outcome was clinical response to CBD (≥50% or <50% seizure reduction at 1, 3, and 6 months after CBD introduction and the last follow-up visit). Relevant adverse events were monitored. Results: Thirty patients were included. The median age of epilepsy onset was 5.5 years (interquartile range [IQR], 3.3 to 25.3), with a median treatment duration of CBD of 6 months (IQR, 3.3 to 7.0). Sixteen patients (53.3%) showed ≥50% seizure reduction at the last follow-up. In a univariate analysis, patients whose epilepsy commenced after 3 years of age were more likely to respond to CBD (odds ratio, 10.11; 95% confidence interval, 1.05 to 97.00; P=0.04). Adverse events were observed in 11 patients (36.6%); the most common adverse event was somnolence. Conclusion: CBD could be a treatment option for children and young adults with drug-resistant LGS with a tolerable safety profile. Age at epilepsy onset (>3 years) was associated with a favorable response to CBD treatment. Further prospective studies with larger populations are needed to evaluate the tolerability and efficacy of CBD in patients with drug-resistant epilepsy of various etiologies.

show abstract

“…In Asia, one study retrospectively evaluated the use of CBD in 42 patients with DS or LGS in South Korea and found that 33.3% of patients who received CBD at a dose of 10 mg/kg/day had at least a 50% reduction in seizure frequency after 3 months. 39…”

Section: Emjmentioning

confidence: 99%

Cannabinoids in the Treatment of Epilepsy: A Review

Zhou

Dennis

Snehal

et al. 2021

EMJ

View full text Add to dashboard Cite

Cannabinoids have been studied for their role in the treatment of epilepsy for many years. The U.S. Food and Drug Administration (FDA) approved them for the treatment of some refractory syndromes in 2018. Cannabidiol and tetrahydrocannabinol are the most commonly studied cannabinoids and have been studied in great depth vis-à-vis their pharmacokinetics and pharmacodynamics. Studies have shown the efficacy of cannabinoids in the treatment of refractory epilepsy. A substantial amount of research has been performed exploring the interactions between cannabinoids and other conventional antiseizure medications. The exact mechanisms by which cannabinoids exert their effects on seizure control remain unclear and research into these mechanisms continues in great earnest. Cognitive changes from cannabinoids are constantly being studied and add to potential benefits from the use of these compounds. Cultural and social misconceptions and roadblocks about the use of cannabinoids persist and represent an ongoing obstacle to increasing research and therapeutic use of these compounds. This review focuses on all these aspects and of the use of these cannabinoids in the treatment of epilepsy and seeks to offer a fairly comprehensive description of the facets of cannabinoid therapy for refractory epilepsy.

show abstract

Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea

Cited by 20 publications

References 24 publications

Cannabidiol (CBD) Reduces Epileptic Seizures in the Asian Population: Cross-sectional Study for Intractable Epilepsy Patients in Japan

Cannabidiol (CBD) Reduces Epileptic Seizures in the Asian Population: Cross-sectional Study for Intractable Epilepsy Patients in Japan

Cannabidiol Treatment for Lennox-Gastaut Syndrome at a Single Tertiary Center in South Korea

Cannabinoids in the Treatment of Epilepsy: A Review

Contact Info

Product

Resources

About